Healthcare
Live Price
Offline$23.67
+1.11% today
1Y Change
+8.33%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Privia Health Group, Inc. (PRVA) is a Healthcare stock with a market cap of $3.12B and listed on NASDAQ. The stock last traded around $23.67 and up 8.3% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +22.3%, EPS growth of +58.3%, a dividend yield of 0.0%. What stands out right now is revenue +22.3%, EPS +58.3%, free cash flow +55.6% with operating margin 1.6% and ROIC 2.9%. Valuation already assumes a fairly strong business story at P/E 133.6 and price/sales 1.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRVA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRVA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRVA Max Drawdown
-24.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRVA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$966.2M
-28.8% YoY
FY Net Income
-$188.2M
-2092.5% YoY
Free Cash Flow
$54.5M
+15.8% YoY
Revenue Growth
+22.3%
EPS Growth
+58.3%
Gross Margin
9.6%
Net Margin
1.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.1B | 1.7B | 1.7B | 1.4B | 966M |
| Gross Profit | 209M | 177M | 162M | 135M | 64M |
| Operating Income | 34M | 17M | 21M | -19M | -217M |
| EBITDA | 44M | 24M | 27M | -15M | -215M |
| Net Income | 23M | 14M | 23M | -9M | -188M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 480M | 491M | 390M | 348M | 321M |
| Total Assets | 1.4B | 1.1B | 1000M | 793M | 686M |
| Total Liabilities | 578M | 452M | 393M | 274M | 236M |
| Shareholder Equity | 737M | 635M | 561M | 499M | 427M |
| Total Debt | 10M | 6M | 8M | 12M | 46M |
| Net Debt | -470M | -486M | -381M | -336M | -274M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
55M
+16.7% YoY
Capital Expenditures
547K
-426.0% YoY
Free Cash Flow
55M
+15.8% YoY
Key ratios
Gross Margin
9.6%
Operating Margin
1.6%
Net Margin
1.1%
ROE
3.3%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.